Cargando…
Persistence of SARS-CoV-2-specific antibodies in COVID-19 patients
To better understand humoral immunity following SARS-CoV-2 infection, 114 hospitalised COVID-19 patients with antibody monitored over 8 weeks from symptom onset were retrospectively investigated. A total of 445 serum samples were assessed via chemiluminescence immunoassay. Positive rate of virus-spe...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724312/ https://www.ncbi.nlm.nih.gov/pubmed/33310664 http://dx.doi.org/10.1016/j.intimp.2020.107271 |
_version_ | 1783620517619564544 |
---|---|
author | Wang, Yanan Li, Jingjing Li, Huijun Lei, Ping Shen, Guanxin Yang, Chunguang |
author_facet | Wang, Yanan Li, Jingjing Li, Huijun Lei, Ping Shen, Guanxin Yang, Chunguang |
author_sort | Wang, Yanan |
collection | PubMed |
description | To better understand humoral immunity following SARS-CoV-2 infection, 114 hospitalised COVID-19 patients with antibody monitored over 8 weeks from symptom onset were retrospectively investigated. A total of 445 serum samples were assessed via chemiluminescence immunoassay. Positive rate of virus-specific IgM reached up to over 80% from the second week to the eighth week after symptom onset, then declined quickly to below 30% in the twelfth week. Concentrations of IgG remained high for at least 3 months before subsequently declining. As compared with the non-severe group, serum IgM level from week 3 to week 8 was significantly higher among the patients with severe clinical symptoms (P = 0.012) but not IgG (P = 0.053). Serum IgM level from week 3 to week 8 was correlated with positive virus RNA test (r = 0.201, P = 0.044), albumin level (r = −0.295, P = 0.003), lactic dehydrogenase (LDH) level (r = 0.292, P = 0.003), alkaline phosphatase (ALP) level (r = 0.254, P = 0.010), C-reactive protein (CRP) level (r = 0.281, P = 0.004) during the same course, while serum IgG level was correlated with age (r = 0.207, P = 0.038). This presented results provide insight into duration of SARS-CoV-2 antibodies and interaction between the virus and host systems. |
format | Online Article Text |
id | pubmed-7724312 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77243122020-12-10 Persistence of SARS-CoV-2-specific antibodies in COVID-19 patients Wang, Yanan Li, Jingjing Li, Huijun Lei, Ping Shen, Guanxin Yang, Chunguang Int Immunopharmacol Article To better understand humoral immunity following SARS-CoV-2 infection, 114 hospitalised COVID-19 patients with antibody monitored over 8 weeks from symptom onset were retrospectively investigated. A total of 445 serum samples were assessed via chemiluminescence immunoassay. Positive rate of virus-specific IgM reached up to over 80% from the second week to the eighth week after symptom onset, then declined quickly to below 30% in the twelfth week. Concentrations of IgG remained high for at least 3 months before subsequently declining. As compared with the non-severe group, serum IgM level from week 3 to week 8 was significantly higher among the patients with severe clinical symptoms (P = 0.012) but not IgG (P = 0.053). Serum IgM level from week 3 to week 8 was correlated with positive virus RNA test (r = 0.201, P = 0.044), albumin level (r = −0.295, P = 0.003), lactic dehydrogenase (LDH) level (r = 0.292, P = 0.003), alkaline phosphatase (ALP) level (r = 0.254, P = 0.010), C-reactive protein (CRP) level (r = 0.281, P = 0.004) during the same course, while serum IgG level was correlated with age (r = 0.207, P = 0.038). This presented results provide insight into duration of SARS-CoV-2 antibodies and interaction between the virus and host systems. Elsevier B.V. 2021-01 2020-12-09 /pmc/articles/PMC7724312/ /pubmed/33310664 http://dx.doi.org/10.1016/j.intimp.2020.107271 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Wang, Yanan Li, Jingjing Li, Huijun Lei, Ping Shen, Guanxin Yang, Chunguang Persistence of SARS-CoV-2-specific antibodies in COVID-19 patients |
title | Persistence of SARS-CoV-2-specific antibodies in COVID-19 patients |
title_full | Persistence of SARS-CoV-2-specific antibodies in COVID-19 patients |
title_fullStr | Persistence of SARS-CoV-2-specific antibodies in COVID-19 patients |
title_full_unstemmed | Persistence of SARS-CoV-2-specific antibodies in COVID-19 patients |
title_short | Persistence of SARS-CoV-2-specific antibodies in COVID-19 patients |
title_sort | persistence of sars-cov-2-specific antibodies in covid-19 patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724312/ https://www.ncbi.nlm.nih.gov/pubmed/33310664 http://dx.doi.org/10.1016/j.intimp.2020.107271 |
work_keys_str_mv | AT wangyanan persistenceofsarscov2specificantibodiesincovid19patients AT lijingjing persistenceofsarscov2specificantibodiesincovid19patients AT lihuijun persistenceofsarscov2specificantibodiesincovid19patients AT leiping persistenceofsarscov2specificantibodiesincovid19patients AT shenguanxin persistenceofsarscov2specificantibodiesincovid19patients AT yangchunguang persistenceofsarscov2specificantibodiesincovid19patients |